BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
Status:
Active, not recruiting
Trial end date:
2028-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well radiation therapy with or without apalutamide works in
treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray
to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer
cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving
radiation therapy and apalutamide may work better at treating prostate cancer than radiation
alone.